Avery Spitz

651 total citations
12 papers, 484 citations indexed

About

Avery Spitz is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Avery Spitz has authored 12 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Avery Spitz's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Hormonal and reproductive studies (6 papers). Avery Spitz is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Hormonal and reproductive studies (6 papers). Avery Spitz collaborates with scholars based in United States, Sweden and Germany. Avery Spitz's co-authors include Samuel R. Denmeade, Mario A. Eisenberger, Michael A. Carducci, Michael T. Schweizer, Emmanuel S. Antonarakis, Hao Wang, Jun Luo, Haiyi Cao, Michael C. Haffner and John T. Isaacs and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Lancet Oncology.

In The Last Decade

Avery Spitz

12 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Avery Spitz United States	4	380	180	155	151	79	12	484
Oliver Sartor United States	10	346 0.9×	97 0.5×	120 0.8×	90 0.6×	98 1.2×	22	437
Erik Bovinder Ylitalo Sweden	7	505 1.3×	231 1.3×	162 1.0×	126 0.8×	198 2.5×	12	614
Reetta Riikonen Finland	6	283 0.7×	153 0.8×	106 0.7×	58 0.4×	110 1.4×	19	433
Rana Sullivan United States	10	323 0.8×	349 1.9×	66 0.4×	259 1.7×	86 1.1×	19	643
Nicholas I. Simon United States	11	521 1.4×	240 1.3×	178 1.1×	154 1.0×	253 3.2×	31	720
Eric G. Bluemn United States	4	486 1.3×	302 1.7×	145 0.9×	100 0.7×	195 2.5×	8	618
Shivang Doshi United States	4	406 1.1×	184 1.0×	117 0.8×	80 0.5×	197 2.5×	5	528
A. Seun Ajiboye United States	4	193 0.5×	170 0.9×	92 0.6×	85 0.6×	65 0.8×	6	359
Dan Brigham	3	398 1.0×	174 1.0×	112 0.7×	67 0.4×	180 2.3×	4	461
Ellen S. de Morrée Netherlands	8	394 1.0×	154 0.9×	69 0.4×	122 0.8×	179 2.3×	10	544

Countries citing papers authored by Avery Spitz

Since Specialization

Citations

This map shows the geographic impact of Avery Spitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avery Spitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avery Spitz more than expected).

Fields of papers citing papers by Avery Spitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avery Spitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avery Spitz. The network helps show where Avery Spitz may publish in the future.

Co-authorship network of co-authors of Avery Spitz

This figure shows the co-authorship network connecting the top 25 collaborators of Avery Spitz. A scholar is included among the top collaborators of Avery Spitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avery Spitz. Avery Spitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Gafita, Andrei, Andrew F. Voter, Avery Spitz, et al.. (2024). Initial Experience with [¹⁷⁷Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction. Journal of Nuclear Medicine. 65(11). 1724–1730. 3 indexed citations

Spitz, Avery. (2023). Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling. Clinical journal of oncology nursing. 27(5). 539–547. 2 indexed citations

Rowe, Steven P., Mohammad Salehi Sadaghiani, Andrei Gafita, et al.. (2023). Prostate-Specific Membrane Antigen-Ligand Therapy. Radiologic Clinics of North America. 62(1). 177–187. 1 indexed citations

Teply, Benjamin A., Hao Wang, Brandon Luber, et al.. (2017). Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet Oncology. 19(1). 76–86. 137 indexed citations

Schweizer, Michael T., Hao Wang, Brandon Luber, et al.. (2016). Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. The Prostate. 76(13). 1218–1226. 64 indexed citations

Teply, Benjamin A., Emmanuel S. Antonarakis, Michael A. Carducci, et al.. (2015). A randomized phase II study comparing bipolar androgen therapy vs. enzalutamide in asymptomatic men with castration resistant metastatic prostate cancer: The TRANSFORMER trial.. Journal of Clinical Oncology. 33(15_suppl). TPS5079–TPS5079. 2 indexed citations

Schweizer, Michael T., Emmanuel S. Antonarakis, Hao Wang, et al.. (2015). Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine. 7(269). 269ra2–269ra2. 182 indexed citations

Schweizer, Michael T., Emmanuel S. Antonarakis, Hao Wang, et al.. (2014). A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 32(4_suppl). 45–45. 1 indexed citations

Пили, Роберто, Mario A. Eisenberger, Avery Spitz, et al.. (2010). A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology. 67(2). 431–438. 1 indexed citations

10.

Spitz, Avery, et al.. (2010). Efficacy and safety of 6-month depot leuprolide acetate for the treatment of prostate cancer: Results of a 48-week study.. Journal of Clinical Oncology. 28(15_suppl). e15042–e15042. 1 indexed citations

11.

Li, Jing, Mats O. Karlsson, Julie R. Brahmer, et al.. (2006). CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. JNCI Journal of the National Cancer Institute. 98(23). 1714–1723. 89 indexed citations

12.

Brahmer, Julie R., Antonio Jimeno, Sharyn D. Baker, et al.. (2006). Evaluation of gefitinib biological effects in patients with solid tumors amenable to sequential biopsies—Final results. Journal of Clinical Oncology. 24(18_suppl). 3090–3090. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact